The invention relates to an AIDS biotherapy reactor, and belongs to the field of bio-
medicine. The AIDS biotherapy reactor is characterized in that by changing the genetic structures of T cells through exogenous
gene integration, an immortal
cell line is prepared and CD4+ cells, which can bond HIV and can generate
cell factors, are prepared by taking
T cell surface antibodies as
cell growth activators through artificial industry, and the immortal cell line is covered by virtue of a high-
biocompatibility material, so that the reactor is prepared, wherein the reactor not only can prevent the
filtration-out of the cells and debris thereof and even the HIV but also can offer a place to the CD4+ cells to generate the cell factors and to bond the HIV; when
plasma, which is isolated
in vitro, passes through the reactor, the HIV, which is bonded with the CD4+ cells or enter the cells, is scavenged, and meanwhile, the generated cell factors, along with the
plasma, flow out from intercellular spaces and then return into a body, so that an artificial CD4+
T cell substitutive therapy by which the HIV is introduced out of the body and is scavenged and the cell factors are supplemented is achieved; and the substitutive therapy, in comparison with a conventional therapy which is limited in killing the HIV
in vivo but is difficult to implement, is more feasible and is free from toxic and side effects.